Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study.
about
Toxicity of a 24-hour infusion of gemcitabine in biliary tract and pancreatic cancer: a pilot study.Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: a phase I studyA 21-day schedule of gemcitabine and cisplatin administration in the treatment of advanced non-small cell lung carcinoma: a phase II studyNeoadjuvant gemcitabine-based accelerated hyperfractionation chemoradiotherapy for patients with borderline resectable pancreatic adenocarcinoma.Phase I trial of radiotherapy concurrent with twice-weekly gemcitabine for head and neck cancer: translation from preclinical investigations aiming to improve the therapeutic ratio.On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer.Mistletoe and gemcitabine in patients with advanced cancer: a model for the phase I study of botanicals and botanical-drug interactions in cancer therapy.A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignanciesA phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer.Phase I study of gemcitabine using a once every 2 weeks schedule.Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma.D- and L-2',3'-didehydro-2',3'-dideoxy-3'-fluoro-carbocyclic nucleosides: synthesis, anti-HIV activity and mechanism of resistanceInterleukin 6 is a cause of flu-like symptoms in treatment with a deoxycytidine analogue.Intraoperative and early postoperative chemotherapy into the abdominal cavity using gemcitabine may prevent postoperative occurence of peritoneal carcinomatosis.
P2860
Q33341524-AB7EB4CF-BC19-438C-ACA6-9B68A9DEE6B7Q33365043-9F149A60-7491-4DBF-8DC0-3EB8820AADD9Q33389166-BB28A0E9-09BE-473D-8B00-56BAAA4D1C84Q33418870-D7635BC0-54C0-4A36-B627-6A49C0557308Q34369298-611FEB35-CC3C-4295-B6F7-759EB8D7F4A2Q34810768-DCA8608F-AC80-4712-A9FC-7BB2F38B05A6Q35624530-00634B12-CB1D-456C-8FF3-E071526C3702Q35640393-CADC14E4-1BCF-4D23-9A02-7843E3F1957AQ36135699-FE5A6349-AEBE-49C5-8D61-90DB8A9ACB6DQ36431498-24C986A2-1A28-4D93-835A-165E77F53F76Q36614865-2ADD9F39-C891-45A3-B961-A516D2854197Q36870648-8FC1815A-B0A1-43F1-AA40-2DE9E8B9B770Q39707448-C2810DEE-EBE3-4E63-83AC-1C4A1C248821Q40761194-5AE5CFC9-C753-4F62-9739-4C2E7FEEAF3E
P2860
Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study.
description
1992 nî lūn-bûn
@nan
1992 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
name
Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study.
@ast
Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study.
@en
type
label
Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study.
@ast
Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study.
@en
prefLabel
Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study.
@ast
Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study.
@en
P2093
P356
P1476
Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study.
@en
P2093
B G Redman
E A Poplin
L Flaherty
M Valdivieso
P Tarasoff
P2888
P304
P356
10.1007/BF00877241
P577
1992-08-01T00:00:00Z
P6179
1007969609